Exelixis
EXEL
#1585
Rank
NZ$24.40 B
Marketcap
NZ$97.09
Share price
2.89%
Change (1 day)
34.70%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2026 (TTM): NZ$1.71 Billion

According to Exelixis's latest financial reports the company's current earnings are NZ$2.37 Billion. In 2025 the company made an earning of NZ$1.66 Billion, an increase over its 2024 earnings that were of NZ$1.20 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.71 B2.79%
2025 NZ$1.66 B38.08%
2024 NZ$1.20 B164.69%
2023 NZ$0.45 B9.89%
2022 NZ$0.41 B-20.33%
2021 NZ$0.52 B124.82%
2020 NZ$0.23 B-67.14%
2019 NZ$0.70 B-11.94%
2018 NZ$0.80 B185.09%
2017 NZ$0.28 B-325.82%
2016 -NZ$0.13 Billion-58.12%
2015 -NZ$0.3 Billion-37.61%
2014 -NZ$0.48 Billion9.75%
2013 -NZ$0.44 Billion65.96%
2012 -NZ$0.27 Billion-291.63%
2011 NZ$0.13 B-195.59%
2010 -NZ$0.15 Billion-42.17%
2009 -NZ$0.25 Billion-18.98%
2008 -NZ$0.31 Billion-6.99%
2007 -NZ$0.33 Billion46.3%
2006 -NZ$0.23 Billion33.25%
2005 -NZ$0.17 Billion-30.92%
2004 -NZ$0.25 Billion44.29%
2003 -NZ$0.17 Billion12.86%
2002 -NZ$0.15 Billion22.79%
2001 -NZ$0.13 Billion60.14%
2000 -NZ$75.99 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
NZ$46.05 B 2,489.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$18.77 B 955.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$16.10 B 805.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$13.57 B 663.41%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$23.31 B 1,211.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$17.01 B 856.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$17.74 B 897.95%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-NZ$57.72 Million-103.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-NZ$51.48 Million-102.89%๐Ÿ‡บ๐Ÿ‡ธ USA